Baltimore Innovation Week 2017

Tim is the Director of Emerging Technologies at Mind Over Machines where he helps clients build for the future with practical innovation. Prior to working at Mind Over Machines Tim has been a technology leader at companies ranging in size from global enterprises to local startups in the Baltimore/Washington area. Tim is a frequent guest speaker on technology topics, has a passion for helping others build their careers and is a contributor to local, national & global publications including MSDN Magazine.

Ronan Perry is a sophomore at the Johns Hopkins University, double majoring in Biomedical Engineering and Applied Math, and originally from Ithaca, NY.

Sarah Jennings started building things as soon as she was big enough to hold a hammer, and hasn't stopped since. As the Creative Director of Brand and Ad Innovation at OATH, she is obsessed with making the advertising world a better place for consumers of content. Sarah came to Oath through AOL and Millennial Media, where she built mind blowing creatives for big brands on every kind of small screen since phones had internet. She was named one of Business Insider's 30 most creative people in mobile advertising, and loves sharing her excitement about the power of technology with anyone who will listen. Sarah's previous life was as a propsmaster and costumer, graduating from UVA and working at opera houses and other theaters around Europe and the United States. Sarah learned how to build pretty much any physical object during that time, but became more and more interested in what could be built on computers. She got her masters in Publication Design from the University of Baltimore and started working in ad tech. Sarah always tries to bring an element of spectacle to every project, digital or otherwise. When she's not getting paid to play on her phone, she spends her time with the best thing she ever made - her daughter Riley.

Michelle Menard is an award wining game designer, published author (Game Development with Unity), and 10-year veteran of the industry. She has previously worked in both the mobile and AAA market, and as a consultant under Artemic Games, LLC, partnering with other companies to provide core system design, itemization, auditing, and documentation. Once she was invited to the White House to blabber about game design and crowd-sourcing for big data. Michelle is currently the lead designer at Oxide Games, and is also a co-founder of Fishwizard Games, a small boardgame company exploring strategy games set in the Gateway universe. Gateway: Uprising, their first title, is due out in stores Q3 of this year.

Michelle also serves as an adjunct professor at UMBC and SCAD, teaching game design, theory, and game history, and has taught intro C# game development courses for the local non-profit Code in the Schools. She holds a double BA in Applied Mathematics and Music Theory from Brown University, and an MFA in Game and Interactive Design from SCAD.

Dan Rodricks is an award-winning columnist for the Baltimore Sun newspapers, and host of the Roughly Speaking podcast. He was previously the host of Midday, a daily talk show on WYPR FM 88.1, the NPR station in Baltimore, and the host of "Rodricks For Breakfast" on WMAR-TV, "The Dan Rodricks Show" on WBAL Radio , and a long-time contributor of features and commentary to WBAL-TV.

Dr. Abigail McElhinny joined Personal Genome Diagnostics as Senior Vice President, Research & Development and Operations in May 2016 from Ventana Medical Systems (Roche Tissue Diagnostics), where she held a number of different roles of increasing responsibilities. At Ventana, Abigail held the position as Vice President of Assay and Reagent Development where she built and led Research & Development teams with the goal of developing new assays for the BenchMark and next generation platforms. Dr. McElhinny represented Ventana on the pivotal PD-L1 Blueprint initiative, and successfully oversaw key scientific projects critical to the business, while her organization doubled in size. Abigail previously served as Senior Project Leader for CDx lifecycle projects, working with regulatory, clinical affairs, quality, and biostatistics teams to build the necessary processes and requirements to support pharma clinical trials and obtain FDA approval for CDx assays, including Ventana’s ALK (D5F3) CDx IHC assay and HER2 Dual ISH assays. Abigail received her Ph.D. from Northeastern University in Immunology and Biochemistry, and completed a post-doctoral fellowship at University of Arizona in Cell Biology, focused on molecular mechanisms of cardiac muscle development, cardiomyopathies and muscle remodeling.

Le`Rhone is part of the technology leadership at The Archer Group and oversees the front end development and animation disciplines. He also oversees emerging technology research via the Archer Innovations program. This team is currently exploring Virtual Reality, Machine Learning, and Artificial Intelligence, and uses this research to educate internal teams and find new opportunities to create meaningful experiences for Archer's clients.

Le’Rhone’s decade of experience in both design and business helps Archer’s work achieve the right balance between meeting the client’s business goals and creating a digital experience worth talking about. He has applied this knowledge to projects for clients such as Wawa Foods, Morgan Stanley, J.P. Morgan Chase, DuPont, March of Dimes, and BarclayCard US.

Founder, Shrenik was motivated to work on Sunrise Health after watching fellow first responders struggle with PTSD and substance use issues in silence due to the social stigma surrounding getting help. After meeting Ravi while at Johns Hopkins, he decided to put his undergraduate education on hold to found Sunrise Health, a mobile application for text-based group psychotherapy that harnesses AI to make mental health care more accessible for patients and more cost-effective for providers. Beyond Sunrise, Shrenik has experience working in business development at multiple medical technology startups, and conducting academic research at Johns Hopkins and the NIH.